期刊文献+

6,7-二(2-甲氧基乙氧基)喹唑啉-4-酮的合成 被引量:3

Synthesis of 6,7-Bis(2-methoxyethoxy)quinazolin-4(3H)-one
下载PDF
导出
摘要 以3,4-二羟基苯甲酸乙酯为原料,通过醚化、硝化、还原、成环四步反应合成新型抗癌药物中间体6,7-二(2-甲氧基乙氧基)喹唑啉-4-酮,改进了工艺,考察了各类工艺条件对目标产物收率的影响,得到最适宜反应条件,在优化条件下,总收率为83.7%。 6,7-Bis(2-methoxyethoxy)quinazolin-4(3H)-one was prepared through etherification,nitration,reduction and cyclization from the starting material ethyl 3,4-dihydroxybenzoate.The synthetic process was improved,and the optimum conditions for the reaction were determined with an overall yield of 83.7%.
出处 《化学世界》 CAS CSCD 北大核心 2010年第4期224-227,231,共5页 Chemical World
基金 江苏省自然科学基金项目(SBK200930370)
关键词 6 7-二(2-甲氧基乙氧基)喹唑啉-4-酮 3 4-二羟基苯甲酸乙酯 抗癌药物 6 7-bis(2-methoxyethoxy)quinazolin-4(3H)-one ethyl 3 4-dihydroxybenzoate anticancer drug
  • 相关文献

参考文献5

  • 1Timothy Norris, Dinos P, Richard S. US: 6 476 040 [P], 2002-11-05.
  • 2Shigeyoshi Nishino, Kenji Hirotsu, Hidetaka Shima. US: 0 276 647A1 [P], 2006-10-07.
  • 3Knesl P, Roseling D, Jordis U. Molecules [J]. 2006 (11) : 286-297.
  • 4李铭东,曹萌,吉民.盐酸埃洛替尼的合成[J].中国医药工业杂志,2007,38(4):257-259. 被引量:10
  • 5Pandey C L, Matsuno E. WO.. 016 351 [P], 2002-10- 03.

二级参考文献6

  • 1王尔兵,王肇炎.分子靶抗癌药:埃洛替尼治疗非小细胞肺癌的新进展[J].癌症进展,2005,3(5):477-480. 被引量:4
  • 2Sorbera LA,Castaner J,Silvestre JS,et al.Erlotinib hydrochloride,oncolytic EGF receptor inhibitor[J].Drugs Future,2002,27 (10):923-934.
  • 3Schnur RC,Arnold LD.Quinazoline derivatives:WO,1996030347[P].1996-10-03.(CA 1996,125:328728)
  • 4Sehnur RC,Arnold LD.Alkynyl and azid-o-substitubed 4-anilinoquinazolines:US,5747498[P].1998-05-05.(CA1998,128:321653)
  • 5Lehner RS,Norris T,Santafianos DP.Processes and intermediates for preparing anti-cancer compounds:JP,2000290262[P].2000-10-17; EP,1044969[P].2000-10-18.(CA 2000,133:281796)
  • 6Jordis U,Knesl P,R(o)seling D.Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines:tandutinib,erlotinib and gefitinib[J].Molecules,2006,11:286-297.

共引文献9

同被引文献36

  • 1王尔兵,王肇炎.分子靶抗癌药:埃洛替尼治疗非小细胞肺癌的新进展[J].癌症进展,2005,3(5):477-480. 被引量:4
  • 2刘刚,宋宝安,桑维钧,杨松,金林红,丁雄.N-取代芳环-4-氨基喹唑啉类化合物的合成及生物活性研究[J].有机化学,2004,24(10):1296-1299. 被引量:19
  • 3张莉,于世英.吉非替尼单药治疗晚期非小细胞肺癌[J].中华肿瘤杂志,2006,28(7):539-541. 被引量:37
  • 4李铭东,曹萌,吉民.盐酸埃洛替尼的合成[J].中国医药工业杂志,2007,38(4):257-259. 被引量:10
  • 5PAWAR V G, SOS M L, RODE H B. Synthesis and biological evaluation of 4-anilinoquinolines as potent Inhibitors of epidermal growth factor re- ceptor [ J]. Journal of Medicinal Chemistry, 2010, 53 (7) :2892 - 2901.
  • 6BLACKHALL F, THATCHER N. Chemotherapy for advanced lung cancer[ J]. European Journal of Cancer,2004, 40:2345 -2348.
  • 7WALLER L L, MILLER A A, PETTY W J. Using erlotinib to treat patients with non-small cell lnng cancer who continue to smoke[ J]. Lung Cancer, 2010, 67:12-16.
  • 8CHANDREGOWDA V, RAO G V, REDDY G C. A process for synthesis of [ 6, 7-bis(2-methoxyethoxy)quinaz-olin-4-yl]-(3-ethynylphenyl) a- mine hydrochloride[ P]. WO200713862, 2007.
  • 9KNESL P, ROSELING D, JORDIS U. Improved synthesis of substituted 6, 7-dihydroxy-4-quinazolinea-mines : tandutinib, erlotinib and gefitinib [J]. Molecules, 2006, 11:286-297.
  • 10Sorbera LA, Castaner J, Silvestre JS. Erlotinib hydrochloride, oncolytic EGF receptor inhibitor [J]. Drugs Future, 2002, 27 (10) : 923-934.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部